Pamiparib and Temozolomide for the Treatment of Hereditary Leiomyomatosis and Renal Cell Cancer

  • STATUS
    Recruiting
  • End date
    Aug 1, 2024
  • participants needed
    21
  • sponsor
    Jonsson Comprehensive Cancer Center
Updated on 4 November 2021
cancer
carcinoma
anticoagulants
serum bilirubin
neutrophil count
pet scan
tumor cells

Summary

This phase II trial investigates how well pamiparib and temozolomide work in treating patients with hereditary leiomyomatosis and renal cell (kidney) cancer. Poly adenosine diphosphate-ribose polymerase (PARPs) are proteins that help repair DNA mutations. PARP inhibitors, such as pamiparib, can keep PARP from working, so tumor cells can't repair themselves, and they may stop growing. Chemotherapy drugs, such as temozolomide, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving pamiparib and temozolomide may help treat patients with hereditary leiomyomatosis and renal cell cancer.

Description

PRIMARY OBJECTIVE:

I. Evaluate response rate of pamiparib plus low-dose temozolomide.

SECONDARY OBJECTIVES:

I. To evaluate the progression-free survival with pamiparib plus low-dose temozolomide.

II. To evaluate the safety (adverse events [AE's]) with pamiparib plus low-dose temozolomide.

TRANSLATIONAL OBJECTIVES:

I. To determine the association between plasma and tumor 2-hydroxyglutarate (2HG), fumarate, and succinate levels and response to treatment.

II. To analyze the association of the genomic mutational signature (by whole genome sequencing) of the tumor to treatment.

OUTLINE

Patients receive orally (PO) twice daily (BID) on days 1-28 and temozolomide PO once daily (QD) on days 1-7. Cycles repeat every 28 days for up to 36 months in the absence of disease progression or unacceptable toxicity.

After completion of study treatment, patients are followed up every 4 months.

Details
Condition Malignant neoplasm of kidney, Renal Cell Carcinoma, Adenocarcinoma, Malignant Adenoma, prcc, Hereditary Papillary Renal Cell Carcinoma, Tubulocystic Renal Cell Carcinoma, Metastatic Renal Cell Carcinoma, Stage III Renal Cell Cancer American Joint Committee on Cancer (AJCC) v8, Metastatic Unclassified Renal Cell Carcinoma, Kidney Cancer, Unresectable Renal Cell Carcinoma, Metastatic Kidney Cancer, papillary renal cell carcinoma, Stage IV Renal Cell Cancer AJCC v8, Hereditary Leiomyomatosis and Renal Cell Carcinoma, Renal Cell Cancer, Clear Cell Papillary Renal Neoplasm, Renal Cancer
Treatment Temozolomide, pamiparib
Clinical Study IdentifierNCT04603365
SponsorJonsson Comprehensive Cancer Center
Last Modified on4 November 2021

Eligibility

Yes No Not Sure

Inclusion Criteria

Subject has voluntarily agreed to participate by signing an informed consent
Eastern Cooperative Oncology Group (ECOG) performance status of =< 1
Ability to swallow whole capsules
Histologically confirmed metastatic or unresectable renal cell carcinoma with morphologic features consistent with hereditary leiomyomatosis and renal cell cancer (HLRCC). This can include tumors with overlapping morphology previously called papillary, tubulocystic, tubulopapillary, collecting duct, or unclassified as long as in the HLRCC- spectrum
The presence of a documented germline fumarate hydratase (FH) alteration (mutation or deletion). This includes pathogenic or likely pathogenic alterations but may also include variants of unknown significance (VUS) in patients with strong personal or family history where the clinician makes a presumed clinical diagnosis
Progression on 1 or more lines of systemic therapies for metastatic disease. Neo/adjuvant therapy in the absence of documented distant disease does not count as a line of therapy
No known intolerance of study drugs or excipients, and able to comply with study requirements
Absolute neutrophil count (ANC) >= 1,500 /microliter (mcL) (< 2 weeks prior to day 1)
Platelets >= 100,000 / mcL (< 2 weeks prior to day 1)
Hemoglobin >= 10 g/dL or >= 6.2 mmol/L without transfusion or erythropoietin (EPO) dependency (within 2 weeks of first dose)
Serum creatinine =< 1.5 x upper limit of normal (ULN) OR measured or calculated creatinine (glomerular filtration rate [GFR] can also be used in place of creatinine or creatinine clearance [CrCl]) >= 40 mL/min for participants with creatinine levels > 1.5 x institutional ULN (< 2 weeks prior to day 1)
Creatinine clearance should be calculated using the standard Cockcroft and Gault equation
Total serum bilirubin =< 1.5 x ULN (total bilirubin must be < 4 x ULN for subject with Gilbert's syndrome) (< 2 weeks prior to day 1)
Aspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase [SGOT]) and alanine aminotransferase (ALT) (serum glutamic pyruvic transaminase [SGPT]) =< 3 x ULN OR =< 5 x ULN for participants with liver metastases (< 2 weeks prior to day 1)
International normalized ratio (INR) or prothrombin time (PT), and activated partial thromboplastin time (aPTT) =<1.5 x ULN unless participant is receiving anticoagulant therapy, and then only as long as PT or PTT is within therapeutic range of intended use of anticoagulants (< 2 weeks prior to day 1)
Female patients of childbearing potential and female partners of male study patients must agree to practice highly effective methods of birth control for the duration of the study and for >= 6 months after the last dose of study drug. In addition, non-sterile male patients must agree to practice highly effective methods of birth control and avoid sperm donation for the duration of the study and for >= 6 months after the last dose of study drug
From the time of the first study-drug treatment through 180 days after the last study drug treatment, male participants must use a condom when 1) having sex with a pregnant woman AND 2) having sex with a woman of childbearing potential
Male and female participants must agree not to donate sperm or eggs, respectively, from the first study-drug treatment through 180 days after the last study drug treatment
Female participants must agree to not breastfeed during the study or for 180 days after the last dose of study treatment
If available, agreement to provide archival tumor tissue for exploratory biomarker analyses
Willingness to undergo a fresh tumor biopsy if deemed safe and feasible by the investigator

Exclusion Criteria

Known hypersensitivity to any temozolomide (TMZ) component
Prior treatment with a PARP inhibitor
Received chemotherapy, biologic therapy, immunotherapy, or investigational agent within 3 weeks (or =< 5 half-lives, whichever is shorter) prior to cycle 1/day 1
Have any unresolved acute effects of any prior therapy of grade 2 or higher, except for AEs not constituting a safety risk by investigator judgment
Had a major surgical procedure (per investigator discretion) =< 4 weeks prior to cycle 1/day 1, or anticipation of need for major surgical procedure during the course of the study
Have other diagnosis of malignancy
Except for surgically excised non-melanoma skin cancer, adequately treated carcinoma in situ of the cervix, localized prostate cancer treated with curative intent, adequately treated low-stage bladder cancer, ductal carcinoma in situ treated surgically with curative intent, or a malignancy diagnosed > 2 years ago, with no current evidence of disease and no therapy =< 2 years prior to day 1
Subject who has received local radiotherapy of non-target lesions for local symptom control within the last 4 weeks must have recovered from any adverse effects of radiotherapy before recording baseline symptoms
Have untreated leptomeningeal or brain metastasis. Subject with previously treated brain metastases is eligible if the metastases have shown no progression on brain computed tomography (CT) or magnetic resonance imaging (MRI) over at least 4 weeks, the subject has no symptoms due to the brain metastases, and the subject has been off corticosteroids for >= 2 weeks
Have active infection requiring systemic treatment
Have known human immunodeficiency virus (HIV) infection
No known chronic active liver disease or evidence of acute or chronic hepatitis B virus (HBV) or hepatitis C (HCV) infection. Patients with prior curative treatment of hepatitis C virus are allowed if treated > 2 weeks prior to treatment previously and HCV ribonucleic acid (RNA) undetectable by established laboratory values
Have any of the following cardiovascular criteria
Current evidence of cardiac ischemia
Current symptomatic pulmonary embolism
Acute myocardial infarction =< 6 months prior to cycle 1/ day 1
Heart failure of New York Heart Association classification III or IV =< 6 months prior to cycle 1/ day 1
Grade >= 2 ventricular arrhythmia =< 6 months prior to cycle 1/ day 1
Cerebral vascular accident (CVA) =< 6 months prior to cycle 1/ day 1
Have an active inflammatory gastrointestinal disease, chronic diarrhea, known diverticular disease or had previous complete gastric resection or lap band surgery
Gastroesophageal reflux disease under treatment with proton pump inhibitors is allowed (assuming no drug interaction potential)
Use or have anticipated need for food or drugs known to be strong or moderate cytochrome P450 (CYP)3A inhibitors or strong CYP3A inducers =< 10 days (or =< 5 half-lives, whichever is shorter) prior to day 1
Are pregnant or nursing (females of childbearing potential require a negative serum pregnancy test =< 7 days before day 1)
Requirement for intravenous (IV) alimentation (at the time of randomization)
Known history of myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML)
Participants must not have received colony stimulating factors (e.g., granulocyte colony-stimulating factor, granulocyte macrophage colony stimulating factor, or recombinant erythropoietin) within 4 weeks prior initiating protocol therapy
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact

site

0/250

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Loading...

Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note